Skip to main content

Advertisement

SpringerLink
Log in

Skeletal-related events (SREs) in breast cancer patients with bone metastases treated in the nontrial setting

  • Original Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Background

Clinical trials exploring bisphosphonate (BP) use in patients with bone metastases from breast cancer (BC) consistently state skeletal-related event (SRE) rates >50%. These trials predominantly include patients with bone only disease, and also frequently use screening radiology to detect asymptomatic fractures. Both these variables are likely to increase the incidence of SREs and thereby overestimate BP benefit. Little data exists regarding the natural history of SREs among patients treated with i.v. BPs in the nontrial setting.

Materials and methods

Charts from two institutions (PMH and CVH) were reviewed to determine predictive risk factors for SRE development post i.v. pamidronate therapy in BC patients with bone metastases.

Results

Eighty-seven charts from 1999 to 2005 with complete outcome data were identified and reviewed. Pain was the most common presentation for bone metastases occurring in 49 women (56%). At diagnosis, 31 patients (35%) had bone only disease, and 57 (65%) had concomitant visceral metastases. Twenty-nine patients (33%) experienced an SRE prior to commencing BP treatment. Thirty-three women (38%) subsequently developed an SRE after a median of 5 BP treatments. SREs included radiation (79%), pathologic fractures (12%), and hypercalcemia (9%). On Cox regression, baseline history of osteoporosis (HR = 2.8; p = 0.045) and the presence of bone only disease (HR 3.0; p = 0.003) were predictive of SRE development. In patients with and without osteoporosis, median time to SRE was 305 and 866 days, respectively (p < 0.001).

Conclusion

The frequency of SREs in this study was significantly lower than that reported in clinical trials of i.v. BP use. The lower incidence of SREs in this setting could affect sample size calculations for future event-driven BP trials. While the greatest risk of SREs despite BP therapy appears to be in patients with osteoporosis and with metastatic disease confined to the skeleton, further prospective study is merited to confirm and characterize the impact of these risk factors on SRE development.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Coleman RE (2008) Risks and benefits of bisphosphonates. Br J Cancer 98:1736–1740. doi:10.1038/sj.bjc.6604382

    Article  CAS  PubMed  Google Scholar 

  2. Coleman RE, Rubens RD (1987) The clinical course of bone metastases from breast cancer. Br J Cancer 55(1):61–66

    CAS  PubMed  Google Scholar 

  3. Hillner BE, Ingle JN, Chlebowski RT et al (2003) American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21:4042–4057. doi:10.1200/JCO.2003.08.017

    Article  CAS  PubMed  Google Scholar 

  4. Warr D, Johnston M (2004) Use of bisphosphonates in women with breast cancer. Practice guideline report no. 1-11. Hamilton ON: Cancer Care Ontario, Program in Evidence-Based Care; 2004. [Available online at: www.cancercare.on.ca/pdf/pebc1-11f.pdf; cited June 15 2008]

  5. Petrut B, Trinkaus M, Simmons C et al (2008) A primer of bone metastases management in breast cancer. Curr Oncol 15(S1):S50–S57. doi:10.3747/co.2008.176

    Article  CAS  PubMed  Google Scholar 

  6. Pavlakis N, Schmidt R, Stockler M (2005) Bisphosphonates for breast cancer. Cochrane Database Syst Rev CD003474.

  7. Hortobagyi GN, Theriault RL, Lipton A et al (1998) Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate, Protocol 19, Aredia Breast Cancer Study Group. J Clin Oncol 16(6):2038–2044

    CAS  PubMed  Google Scholar 

  8. Theriault RL, Lipton A, Hortobagyi GN et al (1999) Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 17:846–854

    CAS  PubMed  Google Scholar 

  9. Plunkett RA, Smith P, Rubens RD (2000) Risk of complications from bone metastases in breast cancer: implications for management. Eur J Cancer 36:476–482. doi:10.1016/S0959-8049(99)00331-7

    Article  CAS  PubMed  Google Scholar 

  10. Clemons MJ, Dranitsaris G, Cole D et al (2006) Too much, too little, too late to start again? Assessing the efficacy of bisphosphonates in patients with bone metastases from breast cancer. Oncologist 11(3):227–233. doi:10.1634/theoncologist.11-3-227

    Article  CAS  PubMed  Google Scholar 

  11. Gainford C, Dranitsaris G, Clemons M (2005) Recent developments in bisphosphonates for patients with metastatic breast cancer. BMJ 330(7494):769–773. doi:10.1136/bmj.330.7494.769

    Article  CAS  PubMed  Google Scholar 

  12. Gnant M, Mlineritsch B, Schippinger W, et al (2008) Adjuvant ovarian suppression combined with tamoxifen or anastrazole, alone or in combination with zoledronic acid, in premenopausal women with hormone-responsive, stage I and II breast cancer: First efficacy results from ABCSG-12. Plenary Presentation. ASCO Annual Meeting May 30–June 3

  13. Verma S, Kerr-Cresswell D, Dranitsaris G et al (2004) Bisphosphonate use for the management of breast cancer patients with bone metastases: a survey of Canadian medical oncologists. Support Care Cancer 12:852–858. doi:10.1007/s00520-004-0671-9

    Article  PubMed  Google Scholar 

  14. Clemons M, Enright K, Cesta A et al (2004) Do physicians follow systemic treatment and funding policy guidelines? Can J Clin Pharmacol 11:e168–e178

    PubMed  Google Scholar 

  15. Major P, Cook RJ (2008) Natural History of Skeletal Complications in Patients Receiving Chemotherapy for Breast Cancer Metastatic to Bone. Poster Presentation: SABC December 12–14 2008.

  16. Brufsky A (2008) Cancer treatment-induced bone loss: pathophysiology and clinical perspectives. Oncologist 13:187–195. doi:10.1634/theoncologist.2007-0152

    Article  CAS  PubMed  Google Scholar 

  17. Friedlaender GE, Tross RB, Doganis AC et al (1984) Effects of chemotherapeutic agents on bone. Short-term methotrexate and doxorubicin (adriamycin) treatment in a rate model. J Bone Joint Surg Am 66:602–607

    CAS  PubMed  Google Scholar 

  18. Chen Z, Maricic M, Pettinger M et al (2005) Osteoporosis and rate of bone loss among postmenopausal survivors of breast cancer. Results from a Subgroup in the Women’s Health Initiative Observational Study. Cancer 104(7):1520–1530. doi:10.1002/cncr.21335

    Article  PubMed  Google Scholar 

  19. Siris ES, Chen Y-T, Abbott TA et al (2004) Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 164:1108–1112. doi:10.1001/archinte.164.10.1108

    Article  PubMed  Google Scholar 

  20. Lipton A, Theriault RL, Hortobagyi GN et al (2000) Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases. Cancer 88(5):1082–1090. doi:10.1002/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z

    Article  CAS  PubMed  Google Scholar 

  21. Liauw W, Segelov E, Anna L et al (2005) Off-trial evaluation of bisphosphonates in patients with metastatic breast cancer. BMC Cancer 5:89. doi:10.1186/1471-2407-5-89

    Article  PubMed  Google Scholar 

  22. LoRusso P (2001) Analysis of skeletal related events in breast cancer and response to therapy. Semin Oncol 28(suppl 11):22–27. doi:10.1016/S0093-7754(01)90228-3

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology and Medical Oncology, Princess Margaret Hospital and University of Toronto, 610 University Avenue, Toronto, ON, M5G 2M9, Canada

    Mateya Trinkaus, Christine Simmons, George Dranatisaris & Mark Clemons

  2. Department of Medical Oncology, Credit Valley Hospital, Mississauga, ON, Canada

    Jeff Myers

Authors
  1. Mateya Trinkaus
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christine Simmons
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jeff Myers
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. George Dranatisaris
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mark Clemons
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark Clemons.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Trinkaus, M., Simmons, C., Myers, J. et al. Skeletal-related events (SREs) in breast cancer patients with bone metastases treated in the nontrial setting. Support Care Cancer 18, 197–203 (2010). https://doi.org/10.1007/s00520-009-0645-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-009-0645-z

Keywords

Search

Navigation